NEW BRIGHTON, Minn.--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (NYSE PA: ALCLS), the global genome engineering specialist, announces the issuance by the USPTO on May 28, 2013 of a 3rd US patent (US 8,450,471) directed to TAL-effector nucleases.